609-36-9

Basic information

• Product Name: DL-Proline
• Synonyms: H-DL-PYRD(2)-OH;H-DL-PRO-OH;LABOTEST-BB LTBB000673;DL-PROLINE;DL-PYRROLIDINE-2-CARBOXYLIC ACID;DL-2-PYRROLIDINECARBOXYLIC ACID;(+/-)-PYRROLIDINE-2-CARBOXYLIC ACID;PYRROLIDINE-2-CARBOXYLIC ACID
• CAS NO: 609-36-9
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.13
• EINECS: 210-189-3
• Product Categories: Amino Acid Derivatives;Proline [Pro, P];Amino Acids and Derivatives;alpha-Amino Acids;Amino Acids;Biochemistry;Amino Acids;Pyridines
• Mol File: 609-36-9.mol

Chemical Properties

• Melting Point: 208 °C (dec.)(lit.)
• Boiling Point: 215.41°C (rough estimate)
• Flash Point: 106.3 °C
• Appearance: White to off-white/Crystalline Powder
• Density: 1.1808 (rough estimate)
• Refractive Index: 1.4538 (estimate)
• Storage Temp.: Store at RT.
• Solubility: Methanol, Water
• PKA: 2.35±0.20(Predicted)
• Water Solubility: SOLUBLE
• Merck: 14,7780
• BRN: 80809
• CAS DataBase Reference: DL-Proline(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Proline(609-36-9)
• EPA Substance Registry System: DL-Proline(609-36-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 22-24/25-36/37/39-26
• WGK Germany: 3
• F: 3-10
• TSCA: Yes
• Hazardous Substances Data: 609-36-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)

Upstream product

• 41419-12-9 3,3-dichloro-piperidin-2-one 
• 6829-40-9 aminomalonic acid diethyl ester 
• 21761-19-3 (+/-)-5-amino-2-chloro-valeric acid 
• 617-65-2 Glutamic acid 
• 1450-81-3 2,5-dibromopentanoic acid 
• 857975-85-0 5-amino-2,2-dichloro-valeric acid 
• 15647-47-9 5-benzoylaminopentanoic acid 
• 2199-43-1 ethyl 1H-pyrrole-2-carboxylate 
• 6326-44-9 diethyl 2-formylaminomalonate 
• 109-70-6 1.3-chlorobromopropane 
• 109-64-8 1,3-dibromo-propane 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 123-75-1 pyrrolidine 
• 64-18-6 formic acid 

Downstream Products

• 123-75-1 pyrrolidine 
• 56-12-2 4-amino-n-butyric acid 
• 660-88-8 5-aminopentanoic acid 
• 109-52-4 valeric acid 
• 35404-59-2 1-carbamimidoylpyrrolidine-2-carboxylic acid 
• 68047-33-6 1-(N-benzyloxycarbonyl-glycyl)-DL-proline 
• 93001-20-8 1-(4-methanesulfonyl-2-nitro-phenyl)-DL-proline 
• 5768-79-6 tetrahydropyrrolo[1,2-c]imidazol-1,3-dione 
• 10200-25-6 1-(2,4-dinitro-phenyl)-DL-proline 
• 73096-22-7 1-phenylcarbamoyl-DL-proline 
• 22712-58-9 Methylthiohydantoin-Derivat v. Prolin 
• 23500-18-7 DL-Chloracetylprolin 
• 50648-98-1 1-[(2,4-dichloro-phenoxy)-acetyl]-DL-proline 
• 92076-93-2 N-trifluoroacetyl-DL-proline 

Relevant articles and documents

MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF

Provided are a modified IL-7 polypeptide and a fusion protein containing the modified IL-7 polypeptide. The fusion protein of the modified IL-7 includes: a first domain containing an interleukin-7 polypeptide; a second domain containing an oligopeptide having 1 to 10 amino acid residues (with proviso that the second domain excludes the oligopeptide consisting of methionine and/or glycine); and (c) a third domain which prolongs the half-life of the IL-7 fusion protein. The modified IL-7 polypeptide is composed of the (a) first domain and the (b) second domain. The modified IL-7 polypeptide and the fusion protein are expressed in a higher yield than the wild-type IL-7 and shows increased stability.

COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLES IN PARTITION-BASED ASSAYS

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

Dudawalamides A-D, Antiparasitic Cyclic Depsipeptides from the Marine Cyanobacterium Moorea producens

A family of 2,2-dimethyl-3-hydroxy-7-octynoic acid (Dhoya)-containing cyclic depsipeptides, named dudawalamides A-D (1-4), was isolated from a Papua New Guinean field collection of the cyanobacterium Moorea producens using bioassay-guided and spectroscopic approaches. The planar structures of dudawalamides A-D were determined by a combination of 1D and 2D NMR experiments and MS analysis, whereas the absolute configurations were determined by X-ray crystallography, modified Marfey's analysis, chiral-phase GCMS, and chiral-phase HPLC. Dudawalamides A-D possess a broad spectrum of antiparasitic activity with minimal mammalian cell cytotoxicity. Comparative analysis of the Dhoya-containing class of lipopeptides reveals intriguing structure-activity relationship features of these NRPS-PKS-derived metabolites and their derivatives.

Anti-fibroblast activation protein antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

METHODS FOR TREATING MUSCLE SPECIFIC RECEPTOR KINASE MYASTHENIA GRAVIS

Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.

FUNCTIONALIZED FLUORINE CONTAINING PHTHALOCYANINE MOLECULES

Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.

REGULATORY NETWORK FOR Th17 SPECIFICATION AND USES THEREOF

Screening assays and methods of using same for screening to identify modulator agents or compounds that affect Th17 cell specification are described herein. Pharmaceutical compositions comprising agents or compounds that modulate Th17 cell specification are also encompassed. Methods for modulating Th17 cell specification using agents identified using assays described herein in pharmaceutical compositions are also envisioned. Such pharmaceutical compositions are useful for treating inflammatory conditions and autoimmune diseases associated with Th17 cell mediated pathology.

DIMERIC BACTERIOPHAGE LYSINS

The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.

Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces

A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition.

TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3)

The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAPβ binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.